StockNews.AI
ABL
StockNews.AI
176 days

Abacus Life Announces Private Exchange of Outstanding Public Warrants

1. Abacus exchanged 4,930,745 warrants for 1,134,071 common shares. This reduces potential dilution. 2. Conversion ratio is 0.23 shares per warrant. It may stabilize future equity dilution. 3. The company uses actuarial technology for uncorrelated alternative investments. This enhances its market positioning. 4. Nearly $3 billion in assets under management with pending acquisitions. Growth prospects may evolve.

8m saved
Insight
Article

FAQ

Why Bullish?

The exchange reduces future dilution risk by converting outstanding warrants into shares, clarifying the capital structure. Past similar transactions have led to improved investor sentiment and near-term share strength.

How important is it?

This transaction addresses a key dilution risk and clarifies the capital base, which can modestly impact ABL's trading profile.

Why Short Term?

The reduction in potential dilution can influence investor sentiment immediately, as seen in comparable corporate restructurings.

Related Companies

ABLLW
February 24, 2025 08:34 ET  | Source: Abacus Life Settlements ORLANDO, Fla., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Abacus Life, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL), a pioneering alternative asset manager specializing in leveraging longevity and actuarial technology to offer uncorrelated investment opportunities, today announced that it has entered into warrant exchange agreements (each, an “Exchange Agreement”) with certain holders (the “Holders”) of its outstanding publicly traded warrants (the “Public Warrants”) to purchase shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”). Pursuant to their respective Exchange Agreements, the Holders agreed to surrender an aggregate of 4,930,745 Public Warrants in exchange for an aggregate of 1,134,071 shares of newly issued Common Stock, representing a ratio of 0.23 shares per warrant.1 The Public Warrants to purchase shares of Common Stock from the Company were issued in connection with the Company’s initial public offering and entitle holders to purchase up to 17,250,000 shares of Common Stock, at an exercise price of $11.50 per share. Each redeemable whole Public Warrant entitles the holder thereof to purchase one share of common stock at a price of $11.50 per full share, subject to adjustment as described in the warrant agreement pursuant to which the Public Warrants were originally issued. The Public Warrants represent a freestanding financial instrument traded on The Nasdaq Stock Market LLC under the symbol “ABLLW” and are legally detachable and separately exercisable from the related underlying shares of Common Stock. About Abacus Abacus is a pioneering global alternative asset manager and market maker specializing in uncorrelated financial products. The Company leverages its longevity data and actuarial technology to purchase life insurance policies from consumers seeking liquidity. This creates a high-return asset class uncorrelated to market fluctuations for institutional investors. With nearly $3 billion in assets under management, including pending acquisitions, Abacus is the only publicly traded global alternative asset manager focused on lifespan-based financial products. Forward Looking Statements All statements in this press release (and oral statements made regarding the subjects of this press release) other than historical facts are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of uncertainties and factors that could cause actual results to differ materially from such statements, many of which are outside the control of Abacus. Forward-looking information includes but is not limited to statements regarding the proposed transaction, including the expected closing of the proposed transaction; Abacus’s financial and operational outlook; Abacus’s operational and financial strategies, including planned growth initiatives and the benefits thereof, Abacus’s ability to successfully effect those strategies, and the expected results therefrom. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “expect,” ‎‎”intend,” “anticipate,” “goals,” “prospects,” “will,” “would,” “will continue,” “will likely result,” and similar expressions (including the negative versions of such words or expressions). While Abacus believes that the assumptions concerning future events are reasonable, it cautions that there are inherent difficulties in predicting certain important factors that could impact the future performance or results of its business. The factors that could cause results to differ materially from those indicated by such forward-looking statements include, but are not limited to: the ‎fact that Abacus’s loss reserves are bases on estimates and may be inadequate to cover ‎its actual losses; the failure to properly price Abacus’s insurance policies; the ‎geographic concentration of Abacus’s business; the cyclical nature of Abacus’s industry; the ‎impact of regulation on Abacus’s business; the effects of competition on Abacus’s business; the failure of ‎Abacus’s relationships with independent agencies; the failure to meet Abacus’s investment ‎objectives; the inability to raise capital on favorable terms or at all; the ‎effects of acts of terrorism; and the effectiveness of Abacus’s control environment, including the identification of control deficiencies. These forward-looking statements are also affected by the risk factors, forward-looking statements and challenges and uncertainties set forth in documents filed by Abacus with ‎the SEC from time to time, including the Annual ‎Report on Form 10-K, as amended, and Quarterly Reports on Form 10-Q and subsequent ‎periodic reports. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Abacus cautions you not to place undue reliance on the ‎forward-looking statements contained in this press release. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Abacus assumes no obligation and, except as required by law, does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Abacus does not give any assurance that it will achieve its expectations. Contacts: Robert Phillips – SVP Investor Relationsrob@abacuslife.com(321) 290-1198 David Jackson – IR/Capital Markets Associatedjackson@abacuslife.com(321) 299-0716 Abacus Life Public Relationspress@abacuslife.com ________________________________1 Bracketed figures to be confirmed.

Related News